REFERENCES

1. Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 1995;19:1-11.

2. Maroja Silvino MC, Venchiarutti Moniz CM, Munhoz Piotto GH, Siqueira S, Galapo Kann A, Dzik C. Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil. Rare Tumors 2013;5:e44.

3. Shetty A, Matrana MR. Renal medullary carcinoma: a case report and brief review of the literature. Ochsner J 2014;14:270-5.

4. Alappan N, Marak CP, Chopra A, Joy PJ, Dorokhova O, Guddati AK. Renal medullary cancer in a patient with sickle cell trait. Case Rep Oncol Med 2013;2013:129813.

5. Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol 2013;37:368-74.

6. Lacovelli R, Modica D, Palazzo A, Trenta P, Piesco G, Cortesi E. Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical literature. Can Urol Assoc J 2015;9:E172-7.

7. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757-63.

8. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, KhooV, Eisen T, Horwich A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25:49-56.

9. Tannir NM, Dubauskas Lim Z, Bekele BN, Johnson ED, Tamboli P, Vaishampayan UN, Plimack ER, Rathmell K, Jonasch E. Outcome of patients (pts) with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): a multicenter experience. J Clin Oncol 2011;29:abstr 386.

10. Albadine R, Wang W, Brownlee NA, Toubaji A, Billis A, Argani P, Epstein JI, Garvin AJ, Cousi R, Schaeffer EM, Pavlovich C, Netto GJ. Topoisomerase II α status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. J Urol 2009;182:735-40.

11. Ezekian B, Englum B, Gilmore BF, Nag UP, Kim J, Leraas HJ, Routh JC, Rice HE, Tracy E. Renal medullary carcinoma: a national analysis of 159 patients. Pediatr Blood Cancer 2017;64:26609.

12. Sodji Q, Klein K, Sravan K, Parikh J. Predictive role of PD-L1 expression in the response of renal medullary carcinoma to PD-1 inhibition. J Immunother Cancer 2017;5:62.

13. Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK. Renal medullary carcinoma: establishing standards in practice. J Oncol Pract 2017;13:414-21.